Abstract
The human homologue of the Drosophila Roundabout gene DUTT1 (Deleted in U Twenty Twenty) or ROBO1 (Locus Link ID 6091), a member of the NCAM family of receptors, was recently cloned from the lung cancer tumour suppressor gene region 2 (LCTSGR2 or U2020 region) at 3p12. DUTT1 maps within a region of overlapping homozygous deletions characterized in both small cell lung cancer lines (SCLC) and in a breast cancer line. In this report we (a) defined the genomic organization of the DUTT1 gene, (b) performed mutation and expression analysis of DUTT1 in lung, breast and kidney cancers, (c) identified tumour specific promoter region methylation of DUTT1 in human cancers. The gene was found to contain 29 exons and spans at least 240 kb of genomic sequence. The 5′ region contains a CpG island, and the poly(A)+ tail has an atypical 5′-GATAAA-3′ signal. We analysed DUTT1 for mutations in lung, breast and kidney cancers, no inactivating mutations were detected by PCR–SSCP. However, seven germline missense changes were found and characterized. DUTT1 expression was not detectable in one out of 18 breast tumour lines analysed by RT–PCR. Bisulfite sequencing of the promoter region of DUTT1 gene in the HTB-19 breast tumour cell line (not expressing DUTT1) showed complete hypermethylation of CpG sites within the promoter region of the DUTT1 gene (−244 to +27 relative to the translation start site). The expression of DUTT1 gene was reactivated in HTB-19 after treatment with the demethylating agent 5-aza-2′-deoxycytidine. The same region was also found to be hypermethylated in six out of 32 (19%) primary invasive breast carcinomas and eight out of 44 (18%) primary clear cell renal cell carcinomas (CC–RCC) and in one out of 26 (4%) primary NSCLC tumours. Furthermore 80% of breast and 75% of CC–RCC tumours showing DUTT1 methylation had allelic losses for 3p12 markers hence obeying Knudson's two hit hypothesis. Our findings suggest that DUTT1 warrants further analysis as a candidate for the tumour suppressor gene (TSG) at 3p12, a region defined by hemi and homozygous deletions and functional analysis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F . 2001 Oncogene 20: 1509–1518
Angeloni D, Wei MH, Timmer T, Van Der Veen AY, Buys CH, Lerman M . 2000 Cancer Genetics and Tumor Suppressor Genes Meeting Cold Spring Harbor Laboratories abstract
Bashaw GJ, Kidd T, Murray D, Pawson T, Goodman CS . 2000 Cell 101: 703–715
Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP . 1998 Adv. Cancer Res. 72: 141–196
Burbee D, Forgacs E, Zöchbauer-Müller S, Shivakuma L, Fong K, Gao B, Randle D, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD . 2001 J. Natl. Cancer Inst. 93: 691–699
Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER . 1998 Genes Chrom. Cancer 22: 200–209
Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP . 2000 Nat. Genet. 25: 315–319
Drabkin HA, Mendez MJ, Rabbitts PH, Varkony T, Bergh J, Schlessinger J, Erickson P, Gemmill RM . 1992 Genes Chrom. Cancer 5: 67–74
Elston CW, Ellis IO . 1991 Histopathology 19: 403–410
Foster K, Osborne RJ, Huddart RA, Affara NA, Ferguson-Smith MA, Maher ER . 1995 Eur. J. Cancer 31A: 2392–2395
Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM et al . 1994 Nat. Genet. 7: 85–90
Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, Baylin SB . 1994 Proc. Natl. Acad. Sci. USA 91: 9700–9704
Huebner K, Garrison PN, Barnes LD, Croce CM . 1998 Annu. Rev. Genet. 32: 7–31
Kaelin Jr WG, Maher ER . 1998 Trends Genet. 14: 423–426
Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SS, Culotti JG, Tessier-Lavigne M . 1996 Cell 87: 175–185
Kidd T, Bland KS, Goodman CS . 1999 Cell 96: 785–794
Kidd T, Brose K, Mitchell KJ, Fetter RD, Tessier-Lavigne M, Goodman CS, Tear G . 1998 Cell 92: 205–215
Kok K, Naylor SL, Buys CH . 1997 Adv. Cancer Res. 71: 27–92
Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan DSR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Paslier D, Chumakov I, Cohen D, Chinault AC, Maher ER, Linehan WM, Zbar B, Lerman MI . 1993 Science 260: 1317–1320
Latif F, Tory K, Modi WS, Graziano SL, Gamble G, Douglas J, Heppell-Parton AC, Rabbitts PH, Zbar B, Lerman MI . 1992 Genes Chrom. Cancer 5: 119–127
Lerman MI, Minna JD, for the International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. 2000 Cancer Res. 60: 6116–6133
Lott ST, Lovell M, Naylor SL, Killary AM . 1998 Cancer Res. 58: 3533–3537
Lovell M, Lott ST, Wong P, El Naggar A, Tucker S, Killiary AM . 1999 Cancer Res. 59: 2182–2189
Lubinski J, Hadaczek P, Podolski J, Toloczko A, Sikorski A, McCue P, Druck T, Huebner K . 1994 Cancer Res. 54: 3710–3713
Man S, Ellis IO, Sibbering M, Blamey RW, Brook JD . 1996 Cancer Res. 56: 5484–5489
Martinez A, Fullwood P, Kondo K, Kishida T, Yao M, Maher ER, Latif F . 2000 Mol. Pathol. 53: 137–144
Martinez A, Walker RA, Shaw JA, Dearing SJ, Maher ER, Latif F . 2001 Mol. Pathol. 54: 300–306
Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER . 2001 Cancer Res. 61: 7277–7281
Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A . 2001 Nature 410: 50–56
Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR, Linnoila RI, Matthews MJ, Bunn Jr PA, Carney D, Minna JD, Mulshine JL . 1996 J. Cell Biochem. 24: Suppl 32–91
Rabbitts P, Bergh J, Douglas J, Collins F, Waters J . 1990 Genes Chrom. Cancer 2: 231–238
Sato K, Tamura G, Tsuchiya T, Endoh Y, Usuba O, Kimura W, Motoyama T . 2001 Br. J. Cancer 85: 199–203
Shaw JA, Walsh T, Chappell SA, Carey N, Johnson K, Walker RA . 1996 Br. J. Cancer 73: 1393–1397
Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, Nagashima Y, Kitamura H, Latif F, Zbar B, Lerman MI, Yao M . 1994 Cancer Res. 54: 2852–2855
Stein E, Tessier-Lavigne M . 2001 Science 291: 1928–1938
Sundaresan V, Chung G, Heppell-Parton A, Xiong J, Grundy C, Roberts I, James L, Cahn A, Bench A, Douglas J, Minna JD, Sekido Y, Lerman MI, Latif F, Bergh J, Li H, Lowe N, Ogilvie D, Rabbitts P . 1998a Oncogene 17: 1723–1729
Sundaresan V, Roberts I, Bateman A, Bankier A, Sheppard M, Hobbs C, Xiong J, Minna JD, Latif F, Lerman MI, Rabbitts P . 1998b Mol. Cell. Neurosci. 11: 29–35
Thoenes W, Storkel S, Rumpelt HJ . 1986 Path. Res. Pract. 181: 125–143
Todd S, Franklin WA, Varella-Garcia M, Kennedy T, Hilliker Jr CE, Hahner L, Anderson M, Wiest JS, Drabkin HA, Gemmill RM . 1997 Cancer Res. 57: 1344–1352
Wistuba II, Behrens C, Milchgrub S, Syed S, Ahmadian M, Virmani AK, Kurvari V, Cunningham TH, Ashfaq R, Minna JD, Gazdar AF . 1998 Clin. Cancer Res. 4: 2931–2938
Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon III JW, Garner HR, McKay B, Latif L, Lerman MI, Lam S, Gazdar AF, Minna JD . 2000 Cancer Res. 60: 1949–1960
Wu JY, Feng L, Park H-T, Havlioglu N, Tang LH, Bacon KB, Jiang Z-H, Zhan X-C, Rao Y . 2001 Nature 410: 948–951
Acknowledgements
This work is supported in part by Cancer Research UK, Breast Cancer Campaign, Lung Cancer SPORE P50 CA70907, and the G Harold and Leila Y Mathers Charitable Foundation. A Martinez is supported by the University of Antioquia, Medellin, Colombia, and a fellowship from COLCIENCIAS.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dallol, A., Forgacs, E., Martinez, A. et al. Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers. Oncogene 21, 3020–3028 (2002). https://doi.org/10.1038/sj.onc.1205421
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205421
Keywords
This article is cited by
-
Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers
Clinical Epigenetics (2021)
-
Highly recurrent CBS epimutations in gastric cancer CpG island methylator phenotypes and inflammation
Genome Biology (2021)
-
G9a regulates tumorigenicity and stemness through genome-wide DNA methylation reprogramming in non-small cell lung cancer
Clinical Epigenetics (2020)
-
PRRG4 promotes breast cancer metastasis through the recruitment of NEDD4 and downregulation of Robo1
Oncogene (2020)
-
Low Expression and Promoter Hypermethylation of the Tumour Suppressor SLIT2, are Associated with Adverse Patient Outcomes in Diffuse Large B Cell Lymphoma
Pathology & Oncology Research (2019)